Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50

Citigroup analyst Eric Joseph has initiated coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating. The firm has set a price target of $50 for the stock.